Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
|Loading, please wait...|
EDIT News Highlights
- EDIT's 30 day story count now stands at 10.
- Over the past 21 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- EMMA, AADI and CASI are the most mentioned tickers in articles about EDIT.
Latest EDIT News From Around the Web
Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair. Ms. Reeve brings over 25 years of value creation in pharmaceutical, medical device and bio-pharma service companies and a successful track record of transitioni
There is no shortage of stocks making big gains. Jason Hawthorne (Danaher): Danaher has been widely recognized for its operational excellence and decentralized model. In fact, its Danaher Business System was profiled in the Harvard Business Review in 2015.
Emma Reeve Editas Medicine today announced that it has appointed Emma Reeve to its Board of Directors. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, Ms.
Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September
Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical t
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Wells Fargo 2021 Virtual Healthcare ConferenceFireside Chat (Virtual)Date: Friday, September 10, 2021Time: 8:00 a.m. ET Morgan Stanley 19th Annual Global Healthcare ConferenceFireside Chat (Virtual)Date: Tuesday, September 14, 2021Time: 9:30 a.m. ET The events will be webcast l
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.